2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 683

Prevalence of Inhibitory or Non-Inhibitory Autoantibodies to Angiotensin Converting Enzyme 2 (ACE2) in Patients with Systemic Lupus Erythematosus
Abstract Number: 1132

Prevalence of Knee Pain in Ultramarathon Runners
Abstract Number: 145

Prevalence of Non-Gout Arthritis in Patients with Gout: Not As Sparing As Previously Thought
Abstract Number: 1855

Prevalence of Potential Drug-Drug and Drug-Condition Interactions in Fibromyalgia Patients Newly-Initiating Pregabalin or Duloxetine
Abstract Number: 567

Prevalence of Psoriasis and Psoriatic Arthritis in a Northern Population of Spain
Abstract Number: 579

Prevalence of Psoriatic Arthritis in Psoriasis Patients According to Newer Classification Criteria
Abstract Number: 1114

Prevalence of Radiographic and Symptomatic Hip Osteoarthritis in an Urban US Population: The Framingham Osteoarthritis Study
Abstract Number: 541

Prevalence of Sacroiliitis in the General Population: Comparative Analysis with Cutaneous Psoriasis and Psoriatic Arthritis
Abstract Number: 2185

Prevalence of Severe Extra-Glandular Manifestations in a Large Cohort of Patients with Primary Sjögren’s Syndrome
Abstract Number: 1700

Prevalence of Spondyloarthritis in Anterior Uveitis Patients: The Sentinel Study
Abstract Number: 1377

Prevalence of Spondyloarthritis-Related Comorbidities, Osteoporosis and Fractures in Ankylosing Spondylitis: a Systematic Literature Review
Abstract Number: 1129

Prevalence of Symptomatic Basilar Thumb Joint Osteoarthritis in the General Population
Abstract Number: 396

Prevalence, Concordance and Predictors of Early and Sustained Remission Assessed by Various Indices in the French Early Arthritis Espoir Cohort
Abstract Number: 2360

Prevalence, Management and Outcomes of PET Positive Large Vessel Vasculitis in Difficult to Treat PMR and GCA Patients
Abstract Number: 174

Prevalence, Risk Factors, and Functional Impact of Arthralgias Among Patients with Chronic Hepatitis C Virus Infection

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].